Trade Summary

Yesterday, Malik Fady Ibraham, serving as EVP Research, Development at Cytokinetics Inc (CYTK), sold 3,500 shares at $77.37 per share, for a total transaction value of $270,795.00. Following this transaction, Malik Fady Ibraham now holds 153,902 shares of CYTK.

This sale represents a 2.00% decrease in Malik Fady Ibraham's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, May 5, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, May 5, 2026, meaning the disclosure happened on the same day as the trade.

Cytokinetics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.